Evidence

BROWSE BY STUDY TYPE OR CONFERENCE
All
  • All
  • MODEL VALIDATION
  • CLINICAL VALIDATION
  • AACR
  • ASCO
  • ASH
BROWSE BY YEAR
All
  • All
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • Archive
Use of biosimulation to predict immune checkpoint inhibitor resistance in patients with high microsatellite instability

AACR,

Cellworks Therapy Response Index Coupled with Personalized Tumor Microenvironment Modeling Predicts Overall Survival for Immunotherapy Treatment in NSCLC Patients

SITC,

Risk Assessment for Drug-Induced Hyperbilirubinemia: A Mechanistic Approach

ACOP,

Use of Biosimulation to Predict Chemotherapy Benefit in Patients with Metastatic NSCLC Being Treated with Immunotherapy

WCLC,

Use of Biosimulation to Predict Concomitant Chemotherapy Benefit in NSCLC Patients with EGFR Mutations Being Treated with Osimertinib

WCLC,

Biosimulation coupled with personalized tumor microenvironment (TME) modeling predicts response to immunotherapy treatment in NSCLC patients

ESMO,

Use of biosimulation to predict homologous recombination deficiency and PARPi benefit in patients with ovarian, pancreatic, prostate and triple negative breast cancers

ESMO,

Integration of genomic aberrations to predict clinical outcomes for patients with gastroesophageal adenocarcinoma receiving neoadjuvant chemotherapy

ESMO Gastrointestinal Oncology,

STAY INFORMED

Top